Family Office

Euclidean Capital

Investment Details

Investor Type
Family Office

Asset Class Focus
Private Equity, Venture Capital, Public Equity, Alternative Investments, Philanthropy

Stage Focus
Early Stage, Growth, Late Stage, Pre-IPO, Buyout

Geographical Focus
United States, Canada, Japan, Australia, Europe, Asia, China, India, Brazil, Mexico, South Korea, Egypt, South Africa, Nigeria, Chile, Argentina, Colombia, Peru, Africa, South America

Industries Focus

  • Financial Services
  • Technology
  • Healthcare
  • Energy
  • Consumer Goods
  • Real Estate
  • Materials
  • Telecommunications
  • Utilities
  • Media
  • Retail
  • Transportation
  • Consumer Services
  • Biotechnology
  • Industrial Goods

Investment Size:
1,000,000 to 50,000,000 USD

Investor Details Founded: 2009

Euclidean Capital is a private investment firm managing the personal wealth of James Simons, founder of Renaissance Technologies. The firm oversees a diversified global investment portfolio across public and private markets, supporting long-term capital preservation, growth, and philanthropic initiatives. Euclidean Capital employs a disciplined investment approach and rigorous risk management, allocating capital to various asset classes, including private equity, venture capital, public equity, alternative investments, and philanthropic endeavors on behalf of the Simons family. The firm's investment strategy encompasses multiple stages, such as early stage, growth, late stage, pre-IPO, and buyout, with a geographical focus spanning the United States, Europe, Asia, Africa, South America, Australia, Canada, Mexico, India, China, Japan, South Korea, Brazil, Argentina, Chile, Colombia, Peru, Egypt, South Africa, and Nigeria. Euclidean Capital's portfolio includes investments in diverse industries, including technology, healthcare, biotechnology, consumer goods, financial services, energy, real estate, media, telecommunications, transportation, industrial goods, materials, utilities, consumer services, and retail. The firm typically invests between $1 million and $50 million in each opportunity, aiming to generate substantial returns while supporting the growth and development of its portfolio companies. Euclidean Capital's commitment to long-term value creation and its diversified investment approach reflect its dedication to preserving and growing the Simons family's wealth across various sectors and geographies.

Requirements
  • Strong management teams
  • Innovative business models
  • Scalable growth potential
  • Competitive market positioning
  • Clear exit strategies
Contact

[Official Website Hidden]

[HQ Location Hidden]

[Email Hidden]

[Contact Number Hidden]

Portfolio Companies
  • 23andMe
  • PMV Pharmaceuticals
  • Alector
  • Surrozen
  • Peltarion
  • April
  • Savvy Wealth
  • Actio Biosciences
  • Neurona Therapeutics
  • Zeitview
  • Leal Therapeutics
  • Judo Bio
  • Nura Bio
  • Circle Pharma
  • Neo Asset Management
Claim this Investor

Are you an official representative of Euclidean Capital?

Claim this investor to update information, manage your profile, and get a verified seal.

Claim